INTRODUCTION
Immunoglobulin light chain (AL) amyloidosis is a progressive plasma cell dyscrasia which is characterized by deposition of amyloid fibers derived from immunoglobulin light chain systemically in many organs 1 .
Amyloidogenic light chains are secreted by clonal plasma cells and, because of the immunoglobulin variability, they are unique to each patient 2, 3 . Characteristics of amyloids related to disease severity and sequelae, including the target organs where amyloids accumulate, such as the heart, kidney, liver and peripheral nerves 3 . Heart failure is usually the critical life-threatening condition; the median survival time depends on the extent of amyloid interference with the critical organ function and survival may range from some months to some years 1, 4 . The incidence in AL amyloidosis is estimated to be somewhat over 3 per million 5, 6 . Monoclonal gammopathy of undetermined significance (MGUS) is often the precursor disease for AL amyloidosis and the related disease multiple myeloma (MM) 7 . It has been reported that some 10 to 15% of multiple myeloma patients have AL amyloidosis 8, 9 ; conversely, some 10% of AL amyloidosis patients have MM at the time of diagnosis 10 . AL amyloidosis and MM share genetic risk loci and the 7 single nucleotide polymorphism (SNPs) initially described for MM were replicated in 443 AL amyloidosis patients with a nominal significance of p<0.05 11 .
We have recently characterized 10 putative genetic risk loci (at significance level of <10 -5 ) for AL amyloidosis using a genome-wide association study (GWAS) approach on a total of 1351 German, UK and Italian patients 12 .
In the present study we carry out a systematic association study on the GWAS identified loci and the available clinical data including the affected organs and the type of serum immunoglobulin (Ig).
METHODS
The patient populations and GWAS analysis have been described elsewhere 12 . Shortly, the German amyloidosis patients (595 passed the GWAS quality control) were ascertained through the Amyloidosis Center at University Clinic Heidelberg. The UK samples (474) were obtained from the National Amyloidosis
Centre, London and the Italian samples (282) came from the Amyloidosis Research and Treatment Center, Pavia. The diagnostic criteria used were as described 13 . DNA was genotyped using Illumina Human
OmniExpress-12 v1.0 and related arrays. Local control populations included 2,107 Germans, 5637 Britons 465 Italians.
A total of 9 clinical profiles were selected among organ involvement (kidney, heart, heart & kidney and liver, irrespective of whether other organs were involved) and Ig profiles (IgG with intact Ig, λ any, κ any, λ/κ light chain only (LCO), and λ LCO).
Analysis of the GWAS data was performed using imputed data as described 12 . All SNPs having a minor allele frequency (MAF) <1% were excluded. The association test between imputed SNPs and AL amyloidosis was performed in SNPTESTv2.5. The three data sets were combined in meta-analysis and heterogeneity was assessed by the I 2 statistic (interpreted as low <0.25, moderate 0.50 and high >0.75).
Genomic locations are given in NCBI Build 37/UCSC hg19 coordinates. For genome-wide significance, a limit of p< 5x10 -8 was used.
In order to test homogeneity of the results between AL amyloidosis and MM ASSET analysis was performed 14 . This method explores all possible subsets for negative, positive, or null associations, identifying the subset with the strongest association signal; it also accounts for the multiple tests required by the subset analysis.
To investigate chromatin state segmentation profiles (ChromHMM) and 3-dimentional interactions (Hi-C) at risk loci we made use of the ENCODE project data on cell lines, including lymphoblastoid cells (GM12878).
We also used HaploReg v4.1 (www.broadinstitute.org/mammals/haploreg) to evaluate the regulatory nature and the possible functional effects of SNPs and their proxies r 2 ≥ 0.8, or 0.95 15 . All relevant data available in HaploReg were considered in the SNP search but when multiple cell types were listed data on hematologic cell types were reported. Association profiles were visualized using the Locuszoom 16 in conjunction with the UCSC genome browser 17 . Z score calculated for SNPs as log OR divided by standard error 18 .
RESULTS
We selected 9 clinical profiles for a specific analysis of GWAS data (Table 1) . Among Ig related profiles, λ any (with or without heavy chains) was the most common one, found in 930 patients. λ/κ LCO was found in 535 patients. Kidney and heart profiles were the largest organ profiles, including over 800 patients each, and liver profile was the smallest with only 194 patients. The median diagnostic ages differed minimally, from 62 to 66 years. The male-female ratio was 1.37 overall and it did not appreciably differ between the profiles. In the bottom of Table 1 data on the MM cohorts are given.
Association analysis and comparison with MM
We carried out a systematic association analysis of each of the 9 clinical profiles against controls in each of the 3 cohorts. Manhattan plots are shown for joint analysis in 4 clinical profiles with genome-wide associations. In the liver profile a genome-wide association, based on imputed SNPs, was noted in chromosome 11 but it had a MAF of 1%; thus few individuals had the variant allele and the association was considered no further.
Among Ig profiles, the λ/κ LCO and the λ LCO profiles showed a strong association with SNP rs9344 ( Table   2 ). The OR for rs9344 OR in the λ/κ LCO profile was 1.62 (p=1.99x10 -12 ) and in the λ LCO profile it was 1.70 (p=1.29x10 -11 ). The weakest association was noted for the IgG profile (1.20, 9.69x10 -3 ), with nonoverlapping 95%CIs to the LCO profiles. For overall AL amyloidosis, the OR was 1.35 and for MM it was 1.06, as reported earlier 12 . Z-scores are also listed because they will be used in figures to be shown later.
For the IgG profile, rs10507419 reached genome-wide significance with an OR of 1.49 and p-value of 5.63x10 -8 . The two subgroups IgG λ and IgG κ showed similar ORs (1.57 and 1.51, respectively) and IgG λ reached genome-wide significance of 2.90x10 -8 (Table 3) . ORs of profiles λ/κ LCO (0.90), λ LCO (0.91), liver (0.98) and κ any (1.00) differed significantly (non-overlapping 95%Cs) from the IgG profile. Among MM subtypes, the OR for IgG MM was 1.01 while the ORs for both IgG λ and IgG κ were 1.00.
Genome-wide association was found for SNP rs6752376 in the heart & kidney profile (OR 1.54, p=2.88 x 10 -8 ) ( Table 4 ). The profiles for kidney and heart only reached ORs of 1.24 and 1.27, respectively. ORs for liver (0.98) and κ any (1.04) profiles differed significantly from the heart & kidney profile. The OR for MM was 1.00.
The liver profile rs7820212 reached genome-wide significance even with a small patient number (194) (OR 1.86, p= 1.86 x 10 -8 ) ( Table 5 ). ORs of all other clinical profiles differed significantly from the liver profile.
The OR for AL amyloidosis overall was 1.07 and for MM it was 1.04.
Of note, there was no or at most moderate heterogeneity for any genome-wide significant associations in Tables 2 to 5 between the 3 AL amyloidosis cohorts as indicated by I 2 . The ORs of the significant associations did not change when stratified for age and sex.
We assessed the associations of the previously described 10 putative candidate SNPs from the combined AL amyloidosis cohorts with each of the 9 profiles 12 . With the exception of SNP rs9344 (Table 2 ) no other SNP associated specifically with AL amyloidosis defined by a clinical profile.
Biological interference
Regional plots of association are shown in Fig. 2 for the genome-wide significant SNPs in 4 clinical profiles.
For the λ/κ LCO profile, rs9344 on chromosome 11q13.3 maps to a splice site in the cyclin D1 gene as shown previously ( Fig. 2A ) 12 . For the IgG profile, SNP rs10507419 on chromosome 13q13.2 maps within the LINC00457 gene (long intergenic non-protein coding RNA 457) of unknown function and resides 330 kb 5' of NBEA (neurobeachin) (Fig, 2B) . ENCODE Hi-C data are lacking for rs10507419 but data are available for the linked SNP (r 2 =1.00) rs9529341, 1 kb away, showing long-range association within the NBEA gene ( Supplementary Fig. 1 , not included 
DISCUSSION
The recent GWAS on these 3 AL amyloidosis cohorts reported 4 SNPs reaching (or almost reaching) a genome-wide significance 12 . With the exception of the most significant SNP, rs9344, none of the other 3
were associated with the defined 9 clinical profiles, probably because of decreased patient numbers.
Interestingly, 3 completely new profile-specific genetic loci were identified with homogeneous results from the 3 cohorts. Independent associations of rs9344 with the two LCO profiles and of rs10507419 with the two IgG profiles show internal consistency.
The preferential association of rs9344 with LCO profiles could possibly be explained by the association of this SNP with translocation (11;14) and the resulting disturbance of IgH production in AL amyloidosis and MM 12, 20, 21 . However no light chain excess has been reported in t(11;14) AL amyloidosis 22, 23 . Data on MM cell line have suggested that compromised production of IgH leads to excess production of free light chains 24 . How rs9344 could interfere with IgH production independent of t(11;14) remains enigmatic. Risk allele G at the splice site of cyclin D1 encodes a full length cyclin D1 which has many functions, including involvement in double-strand repair with RAD51, BRCA1 and BRCA2 and thus a possible interference with the class switch recombination for IgH 25, 26 . Curiously, while the LCO profiles were strongly associated with rs9344, the weakest association was noted for the IgG profile. Conversely, rs10507419 was strongly associated with the IgG profiles while weakly opposite associations were found with this SNP and the LCO profiles. rs10507419 on chromosome 13q13.2 maps close to the NBEA locus (13q13.3) which is a fragile site causing deletion of the telomeric end of chromosome 13q in patients with MM, MGUS and AL-amyloidosis 22, [27] [28] [29] . We found in Hi-C data that rs10507419 shows long-range association with the NBEA locus.
Occasionally NBEA is fused with the tip of chromosome 8q24 containing PVT1 30 . The translocation may interfere with expression of RB1 which is located at 13q14.2 29 .
The possible functions of rs6752378 SNP associated with heart & kidney profile are unknown as are those for the adjacent RNA genes LINC01247 and ACO17053.1. The SNP may influence serum concentration of pantothenate but how this might be related to the heart & kidney profile remain unknown 19 . Liver profile SNP rs7820212 on chromosome 8q11.23 maps close to FAM150A, which is a ligand for receptor tyrosine kinases leukocyte tyrosine kinase (LTK) and anaplastic lymphoma kinase (ALK). These belong to the insulin receptor superfamily, and their aberrant activation has been described in many cancers, such as non-small lung cancer and neuroblastoma in which ALK mutations are common 31, 32 . Fusion genes of ALK are often found in lymphomas with resulting downstream activation of the Ras/Raf/MEK/ERK pathway 33 . rs7820212
is adjacent to the RB1CC1 gene which encodes a protein interacting with pathways involved in regulation of cell growth, proliferation, apoptosis, autophagy, and cell migration 34, 35 . It has tumor suppressor properties in enhancing RB1 (retinoblastoma 1) gene expression in cancer cells and promoting senescence 36 . The SNP changes the binding motif for CEBPB, which is an important transcription factor regulating the expression of genes involved in immune and inflammatory responses. CEBPB may regulate osteoclast activity in MM and through redundant functions with CEBPA it may be involved in multiple cellular processes in hematopoietic cells 37, 38 .
In conclusion, 4 SNPs reached genome-wide associations in clinical profile-specific AL amyloidosis. While the associations were internally consistent and homogeneous between the 3 cohorts the underlying mechanisms remain speculative but tangible. For rs9344 the preference for LCO amyloidosis is another lead to mechanistic understanding. b: Sex-ratio is calculated as male:female ratio for the joined cohort.
c: Data on some clinical profiles were missing in the British cohort. 
